Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J Med Allied Sci. 2022; 12(1): 28-31


ABO and Rhesus blood type severity outcome in COVID-19

Syed Imran Ali, Hajera Rabbani, Farha Tarannum.




Abstract

Novel Corona Virus disease 2019 (COVID-19) is caused by the strain Severe Acute Respiratory Syndrome Corona Virus 2 (SARSCoV-2). Since December 2019 it has rapidly emerged as a pandemic which has spread throughout the world and till date we are finding fresh cases of COVID-19. The current study aims to investigate the ABO, Rhesus blood type susceptibility in COVID-19. A cross sectional retrospective study of 300 COVID 19 cases confirmed by Real Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) with documented ABO, Rhesus (Rh) blood group was carried out. Among 300 COVID-19 cases, 60% were males and 40% were females. The mean age of study population is 54.59±14.18. Out of 300 cases, 80 (26.7%) had blood group O (20 were severe and 60 non-severe cases), 84 (28%) had blood group A (30 were severe and 54 non-severe cases), 116 (38.7%) had blood group B (52 were severe and 64 non-severe cases), 20 (6.7%) had blood group AB (6 were severe and 14 non-severe cases). The proportion of blood group O individuals are less compared to non-O blood group. The blood group B individuals’ proportion is higher in severe and non-severe cases which is statistically significant (p =0.038). Out of 300 cases 270 had Rh positive blood group (90 were severe and 180 non-severe cases) and 30 had Rh negative blood group (18 were severe and 12 non-severe cases) and 67% reduction in severity of covid19 in Rh positive (p=0.004). Current study declares, individuals with blood group O and Rh negative have lesser severity to get infected with SARSCoV-2.

Key words: ABO, COVID-19, Rh blood group, RT-PCR, SARSCoV-2






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.